Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

This trial is testing a five-drug combination (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for newly diagnosed angioimmunoblastic T-cell lymphoma (AITL) — a rare and aggressive type of lymphoma that affects the immune system. These drugs work together through different mechanisms to attack the cancer. **You may be eligible if...** - You have been newly diagnosed with AITL confirmed by biopsy - You have at least one measurable lesion on imaging - You have not received any prior chemotherapy or systemic cancer treatment - You are 18 years or older - Your general health is sufficient to tolerate treatment (ECOG ≤3) - You are expected to live more than 3 months **You may NOT be eligible if...** - You have previously received any systemic treatment for this lymphoma - You have active serious infections or autoimmune conditions - You have severe heart, liver, or kidney disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.